APM - Aptorum Group Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.41
+0.01 (+0.07%)
At close: 11:44AM EDT
Stock chart is not supported by your current browser
Previous Close13.40
Open13.38
Bid13.41 x 900
Ask13.94 x 1100
Day's Range13.38 - 13.42
52 Week Range11.80 - 15.85
Volume6,150
Avg. Volume3,727
Market Cap387.907M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.25
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Trade prices are not sourced from all markets
  • Business Wire8 days ago

    Aptorum Group Limited Reports 2018 Fiscal Year Financial Results and Business Update

    Aptorum Group Ltd. , a preclinical stage pharmaceutical company developing and commercializing a broad portfolio of projects under development of therapeutic and diagnostic technologies to tackle unmet medical needs, today provided a business update and announced financial results for the fiscal year ended December 31, 2018.

  • Business Wire22 days ago

    Aptorum Group Limited Announces Appointment of Head of R&D and Chief Operating Officer

    Aptorum Group Limited (APM) (“Aptorum”) announced today, the appointment of Dr. Thomas Wai-yip Lee as Head of Research and Development (“Head of R&D”) and Dr. Angel Siu-yan Ng as Chief Operating Officer (“COO”) of Aptorum, effective on April 1, 2019. Dr. Thomas Lee joined Aptorum in January 2018 as the Chief Executive Officer and Chief Scientific Officer of Aptorum Therapeutics Limited, a wholly-owned subsidiary of Aptorum. Before joining Aptorum, Dr. Lee was an Assistant Professor at the School of Pharmacy at The Chinese University of Hong Kong.

  • Business Wirelast month

    Aptorum Group Limited to Present at the Barclays Global Healthcare Conference 2019

    Aptorum Group Limited (APM), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced that the start time for the Company’s scheduled presentation at the Barclays Global Healthcare Conference 2019 has been updated to an earlier time slot. The Company will now be presenting on Thursday, March 14th, 2019 at 10:15 a.m. ET. The conference will take place at the Loews Miami Beach Hotel in Miami Beach, Florida and will feature CEOs from industries including Biotechnology, Healthcare Facilities, Managed Care, Specialty Pharmaceuticals, U.S. Pharmaceuticals Life Science Enabling Tool and Healthcare Distribution.

  • Reuters2 months ago

    BRIEF-APM Automotive Posts Qtrly Net Profit Of 17.3 Million RGT

    Feb 25 (Reuters) - APM Automotive Holdings Bhd: * QTRLY REVENUE 382.6 MILLION RGT, QTRLY NET PROFIT 17.3 MILLION RGT * YEAR AGO QTRLY REVENUE 327.5 MILLION RGT ; YEAR AGO QTRLY NET PROFIT 13.1 MILLION ...

  • Business Wire5 months ago

    Aptorum Group Limited Announces Pricing of Initial Public Offering

    Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced that on December 3, 2018, its registration statement on Form F-1, relating to a proposed initial public offering (“IPO” or the “Offering”) of its Class A Ordinary Shares, par value US$1.00 per share (the “Shares”), at a price to the public of $15.80 per share, for gross proceeds of a minimum of US$10 million and up to US$30 million, has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). The Company is offering up to 1,898,734 Shares and up to 51,990 underwriter warrants while certain selling shareholders are offering up to 1,595,235 Shares (collectively, the “Registered Securities”).